Comments
yourfanat wrote: I am using another tool for Oracle developers - dbForge Studio for Oracle. This IDE has lots of usefull features, among them: oracle designer, code competion and formatter, query builder, debugger, profiler, erxport/import, reports and many others. The latest version supports Oracle 12C. More information here.

2008 West
DIAMOND SPONSOR:
Data Direct
SOA, WOA and Cloud Computing: The New Frontier for Data Services
PLATINUM SPONSORS:
Red Hat
The Opening of Virtualization
GOLD SPONSORS:
Appsense
User Environment Management – The Third Layer of the Desktop
Cordys
Cloud Computing for Business Agility
EMC
CMIS: A Multi-Vendor Proposal for a Service-Based Content Management Interoperability Standard
Freedom OSS
Practical SOA” Max Yankelevich
Intel
Architecting an Enterprise Service Router (ESR) – A Cost-Effective Way to Scale SOA Across the Enterprise
Sensedia
Return on Assests: Bringing Visibility to your SOA Strategy
Symantec
Managing Hybrid Endpoint Environments
VMWare
Game-Changing Technology for Enterprise Clouds and Applications
Click For 2008 West
Event Webcasts

2008 West
PLATINUM SPONSORS:
Appcelerator
Get ‘Rich’ Quick: Rapid Prototyping for RIA with ZERO Server Code
Keynote Systems
Designing for and Managing Performance in the New Frontier of Rich Internet Applications
GOLD SPONSORS:
ICEsoft
How Can AJAX Improve Homeland Security?
Isomorphic
Beyond Widgets: What a RIA Platform Should Offer
Oracle
REAs: Rich Enterprise Applications
Click For 2008 Event Webcasts
SYS-CON.TV
Today's Top SOA Links


Funding for Orphan Disease Indication Will Compare EpiVax's Tregitope with IVIG

PROVIDENCE, R.I., Nov. 16, 2012 /PRNewswire/ -- Full Article Here

(Logo:  http://photos.prnewswire.com/prnh/20121116/NE15175LOGO )

Providence-based biotech company EpiVax, Inc. was awarded a new $55,000 grant from the GBS-CIDP Foundation International, to explore using Tregitopes as a novel immuno-modulator therapy for a nerve disease that is currently treated with intravenous immunoglobulin G (IVIG). This award and the recent addition of an SBIR grant for $600,000 to explore the use of Tregitope for Pompe disease (August 2012) will bring the total amount of funding awarded to EpiVax for research and development of Tregitopes to $3.4M in 2012. The surge in funding will result in expansion at the Providence-based biotech company, that is working on spinning off the Tregitope technology into a new venture or angel-backed company.

The GBS-CIDP Foundation research funds will be devoted to developing a safer, more effective replacement for IVIG in the treatment of patients with CIDP (Chronic Inflammatory Demyelinating Polyneuropathy). CIDP patients develop a debilitating nerve condition that requires treatment with IVIG. A single dose of IVIG costs $8,000, and patients often spend tens of thousands of dollars obtaining treatment per year. Alternative treatments that might redirect the immune response toward antigen-specific tolerance without immunosuppressive agents are needed.

The company has been extremely successful in SBIR funding for the Tregitope endeavor despite the constrained funding environment. SBIR grants awarded to EpiVax this year include a Phase I for testing the ability for Tregitopes to reduce inhibitors to FVIII, a separate Phase I SBIR for testing the ability of Tregitopes to reduce immune responses to GAA, a protein that is deficient in Pompe's disease, and a Phase II award to perform safety, toxicity and formulation studies on Tregitopes in the NOD model of Type 1 Diabetes.

About Tregitopes

Tregitopes are linear sequences of peptides contained within the framework of monoclonal antibodies and immunoglobulin-G ,which activate natural regulatory T cells. Tregitopes act as a natural 'off switch' and have been shown in standard preclinical models, and by collaborating laboratories, to suppress and treat autoimmune disease, allergies, and to effectively suppress the immunogenicity of co-administered proteins. This is a natural mechanism for suppressing tissue-destroying immune cells that are the root cause of 'organ-specific autoimmune diseases', in addition, modifying immune responses to biotherapeutics (such as FVIII and other biologics).

Tregitopes were discovered by the team of Anne S. De Groot and Bill Martin at EpiVax.

www.EpiVax.com

CONTACT:  Anthony Marcello, +1-401-272-2123, amarcello@epivax.com

SOURCE EpiVax, Inc.

About PR Newswire
Copyright © 2007 PR Newswire. All rights reserved. Republication or redistribution of PRNewswire content is expressly prohibited without the prior written consent of PRNewswire. PRNewswire shall not be liable for any errors or delays in the content, or for any actions taken in reliance thereon.

Web 2.0 Latest News
Silver shows that predictions in areas such as economics have been less successful, e.g. he examines why many economists missed the recession, and why supposedly expert forecasters get election predictions wrong so often. For example, before the recession of 2008, the assumption was ma...
When we talk about the impact of BYOD and BYOA and the Internet of Things, we often focus on the impact on data center architectures. That's because there will be an increasing need for authentication, for access control, for security, for application delivery as the number of potentia...
Despite the data privacy protections supposedly conferred by regulations like HIPAA and HITECH, consumers’ confidential health and personal information is still not safe enough. That’s the lesson to be learned from Franklin, TN-based Community Health Systems’ (CHS) August 18 regulatory...
Putting on a rock show is like piloting the Millenium Falcon – it’s simultaneously the fastest ship in the galaxy while being a “piece of junk.” The stage lights are so hot you start to sweat immediately, hoping those Jager-bombs are escaping through your pores and delaying the impend...
The IT infrastructure of modern businesses require a number of seemingly never-ending cycles to track assets. As these assets go through different stages of usefulness or functionality, IT teams must constantly manage the process, which takes them away from other more important tasks a...
Subscribe to the World's Most Powerful Newsletters
Subscribe to Our Rss Feeds & Get Your SYS-CON News Live!
Click to Add our RSS Feeds to the Service of Your Choice:
Google Reader or Homepage Add to My Yahoo! Subscribe with Bloglines Subscribe in NewsGator Online
myFeedster Add to My AOL Subscribe in Rojo Add 'Hugg' to Newsburst from CNET News.com Kinja Digest View Additional SYS-CON Feeds
Publish Your Article! Please send it to editorial(at)sys-con.com!

Advertise on this site! Contact advertising(at)sys-con.com! 201 802-3021




SYS-CON Featured Whitepapers
ADS BY GOOGLE